An interventional study of Metformin and Placebo in Stress Resilience, Blood-Brain Barrier Integrity and Mental Health, sponsored by Leibniz-Institut für Resilienzforschung (LIR) gGmbH. Not yet recruiting at 3 sites in 3 countries. Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-11.
Sponsored by Leibniz-Institut für Resilienzforschung (LIR) gGmbH · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Psychological Well-Being with a site in Germany — 19 open to participants now, 22 under way, none of them phase 3. Psychological Well-Being · Germany.
Among the 56 studies in Psychological Well-Being with a site in Germany, this one is the 21st largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2025, is one of 35 with no phase, reaches primary completion later than 13 of the 21 other live ones, and was the 45th registered.
2,208 studies on the registry are indexed under Psychological Well-Being; 730 are open to participants now.
Browse Psychological Well-Being studies →19 of the 56 studies in Psychological Well-Being with a site in Germany are open now. Recruiting first, the newest first:
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 12+
Svenja Taubner · Sites in Germany, Lithuania, Spain and 1 more country
Ages 8+ · Healthy volunteers
Universität Duisburg-Essen · Sites in Germany
Ages 18+
University Hospital Tuebingen · Sites in Germany
Ages 12+
Clara Angela Foundation · Sites in Germany
Ages 18–50 · Women only · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 403 Psychological Well-Being studies recruiting now, 223 (55%) set no upper age limit and 155 (38%) stop at 75 or younger; 121 take children under 18; 206 take healthy volunteers.
This study: 18 Years to 25 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 1
First in 2011; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 122 is above the median of 110 across 1,808 interventional studies indexed under Psychological Well-Being.
Median enrollment 160 across the 37 interventional studies, 360 across the 19 observational. Of the 27 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 56 has an industry lead sponsor. The 10 most frequent:
Leibniz-Institut für Resilienzforschung (LIR) gGmbH is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Leibniz-Institut für Resilienzforschung (LIR) gGmbH has 1 study filed under Psychological Well-Being — fewer than ten, so there is no comparison to draw.
9 of the studies in Psychological Well-Being with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07581171Universitätsklinikum Hamburg-EppendorfCreating Encounters Between Generations - Together Instead of Alone (GemsE) | 2026-12-01 |
| NCT07637422Max Planck Social Neuroscience LabOnline Socio-emotional Dyad Training for Healthcare Professionals' Well-being and Social Skills, Phase II. | 2026-12-20 |
| NCT07637409Max Planck Social Neuroscience LabOnline Socio-emotional Dyad Training for School Teachers' Well-being and Social Skills | 2026-12-20 |
| NCT06965868Leibniz-Institut für Resilienzforschung (LIR) gGmbHRole of the Blood-Brain Barrier in Stress Resilience: Investigating New Pathways Towards Pharmacological Augmentation of Stress Resilience | 2027-02 |
| NCT06633458Universitätsklinikum Hamburg-EppendorfAdolescent Psychiatry Inpatients: Self-reported Parent-adolescent Communication Quality and Treatment Outcome | 2027-03-07 |
Add all 9 to your calendar (.ics) → With an account.
Among the 56 studies in Psychological Well-Being with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to better understand the relationship between blood-brain barrier (BBB) function and stress resilience and to investigate a potential causal role for BBB function in stress resilience in humans. The researchers will look for particpants that are young adults to answer the following questions to reach our goal:
The participants will do the following during our study:
STUDY DESIGN
Prospective, randomized, parallel-group, placebo-controlled, double-blind, multi-center experimental study to investigate the relationship between individual variation in BBB integrity and individual variation in stress resilience in young healthy adult participants at risk for stress-related mental health problems, making use of a 12-week oral administration of Metformin (850 mg twice daily at full dose) as an experimental tool to enhance individual variation in BBB integrity (experimental manipulation). The duration of the study for a participant will be 36 weeks in total. Participants will be assessed at three different study sites (i.e. Mainz, Germany, Zürich, Switzerland, Warsaw, Poland).
The study is divided into 10 phases of 4 weeks each, and has the following study flow and intervention scheme:
OUTCOME MEASURES
Stress resilience is quantified as inverse stressor reactivity (SR). Short-term stress resilience is the average inverse SR score in the 12 weeks after the Experimental Manipulation phase (online monitoring time points T4 to T6). Long-term stress resilience is the average inverse SR score in the 24 weeks after the Experimental Manipulation phase (time points T4 to T9). SR is calculated as an individual's deviation (residual) from a regression of mental health problems [z-standardized sum score of anxiety and depression symptoms, as assessed with the Patient Health Questionnaire - Anxiety and Depression Scale (PHQ-ADS) during online monitoring] on stressor exposure [z-scored sum of occurrences of all daily hassles (DHs), as assessed with the Mainz Inventory of Microstressors (MIMIS) during online monitoring] in the study sample.
Whole-brain BBB integrity is quantified as inverse whole-brain water exchange rate (kw) from blood to brain tissue (BBB permeability), as assessed with neuroimaging before (time point T0) and after the Experimental Manipulation phase (time point T3).
CALCULATING THE SR SCORE
To build the SR score, first, the stressor exposure score E is calculated for every four-weekly monitoring time point after T0 (T1 to T9) as the z-scored sum of occurrences of all daily hassles (DHs), assessed with the MIMIS. Life event (LE) occurrence, assessed with a life-events list, is expected to be less frequent than DH occurrence but, if reported, expected to correlate with DH occurrence. This will be used to corroborate the validity of the DH-based E score. For each monitoring time point, a mental health problem score P is also calculated as the z-standardized sum score of anxiety and depression symptoms, as assessed with the PHQ-ADS. To quantify how strongly participants' mental health problems relate to stressor exposure, the researchers then calculate the relationship between E and P in the analysis sample for a given study phase by fitting a linear mixed model to predict P by E over all included participants and monitoring time points Tx, with random slopes and intercepts for participants. The E-P regression line is then determined by the fixed effect estimates for the EP slope and intercept and serves as the normative E-P relationship for the analysis sample over the study phase of interest. The form of regression that explains most variance in P (linear or quadratic) will be used. At each Tx, the participants' individual E scores will be entered into the normative E-P line equation, giving us their expected P score when assuming normal stressor reactivity. The SR score is the individual's average residual onto the regression line for the study phase of interest.
MEASURING BBB INTEGRITY
A pseudo-continuous ASL (pCASL) MRI sequence will be used to estimate BBB permeability. By reading out pCASL signals at different post-labeling delays (PLD) under different diffusion gradients, perfusion signals in capillary and brain tissues can be reliably estimated and subsequently fitted into a model to estimate the water exchange rate (kw) from blood to brain tissue, an index quantifying BBB permeability. Analysis will use a toolbox provided by the sequence developer (http://loft-lab.org/index-5.html) and includes image reconstruction, preprocessing (motion-correction, coregistration, skull-stripping), and kw modeling. Whole-brain averaged kw values quantifying overall BBB permeability will be calculated. BBB integrity is quantified as inverse permeability.
ADDITIONAL OUTCOME MEASURES
For additional exploratory analyses, blood samples will be taken and used to determine blood-based molecular and cellular markers of immune system, metabolic, and BBB function (including proteins, peptides, RNAs, metabolites). In these additional analyses, BBB integrity will be assessed using both blood-based biomarkers and regional neuroimaging measures (esp. of hippocampus, ventral striatum, and prefrontal cortex), and the association of immunological covariates with BBB integrity and stress resilience will also be considered. Further, socio-demographic and psycho-social variables will be assessed via questionnaire and tested for their association with BBB integrity and stress resilience.
SAMPLE SIZE
Because the association of BBB function in stressor-exposed individuals at risk for stress-related mental health problems with stress resilience (inverse SR score) has never been investigated, the researchers base their power calculation for the primary endpoint on the sensitivity to detect a medium effect size of Cohen's d = 0.3. With a power of 0.8, a two-sided alpha-level of 0.05, and a linear mixed model with eight predictor variables (3 variables of interest and 5 covariates), n=109 participants are needed. Taking into account 10% attrition, our aim is to recruit a total number of 122 participants (61 in each group).
STRATEGIES FOR DATA HANDLING AND THE DISSEMINATION OF RESULTS
Data collection and data management will be conducted in compliance with the principles of the declaration of Helsinki (1996) and relevant national and regional regulations and will only follow study protocols approved by the regional ethics committee at each partner site/country. The investigator at each partner site will be responsible for data management in accordance with these principles. The investigators will collect and process MRI imaging data (digital: DICOM), biosamples (blood), biological data from the analysis of biosamples (digital: concentrations of plasma proteins/peptides, RNAs, metabolites, and other molecules), and computerized (digital: offline and online collection) and paper-and-pencil (analogue) questionnaire and interview data. Data will be made findable with a study description and metadata following fairsharing.org conventions. Open accessibility and data re-use are complicated by the sensitive personal nature of most data and the principled non-anonymizability esp. of MRI data. Participant consent forms will permit sharing of pseudonymized data and biosamples among the sites and with collaborators within the European Union and countries with an adequacy decision under Article 45 GDPR, under the supervision of a Data Use and Access Committee (DUAC). All anonymized data will be made openly accessible through public depositories (in particular, OSF) upon publication or at latest two years after the termination of the project and will remain accessible for at least ten years upon completion of the study.
Inclusion criteria: (participants meeting all of the following criteria will be considered for enrollment in the study)
Exclusion criteria: (participants presenting 1 of the following criteria will not be enrolled in the study)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metformin is used as an experimental tool in the attempt to enhance inter-individual variation in Blood-Brain Barrier integrity in the study sample.
Drug: Metformin
Placebo will be given as a control intervention.
Drug: Placebo
The Metformin intervention will be self-administred capsules, taken during a 12-week period: Four weeks of dose increase; first and second week 500 mg once daily, third and fourth week 500mg twice daily. Full-dose administration (850 mg twice daily) for eight weeks.
This intervention will be self-administered placebo capsules
Average stressor reactivity (SR) score in the 'early follow-up' study phase
SR is the residual deviation of an individual from the sample's normative relation between stressor exposure (E) and mental health problems (P). A positive residual indicates more mental health problems than expected based on the normative E-P relationship. A negative residual (negative SR score) indicates less mental health problems than expected. Hence, SR is an inverse continuous expression of an individual's resilience.
Time frame: From week 13 after enrollment (T4) until week 24 after enrollment (T6)
Whole-brain Blood-Brain Barrier Integrity, assessed with neuroimaging at T0 and T3
A pseudo-continuous ASL (pCASL) MRI sequence will be used to estimate BBB integrity (inverse whole-brain-averaged water exchange rate (kw) from blood to brain tissue).
Time frame: Week 1 after enrollment (T0), before the Experimental Manipulation phase, and week 12 after enrollment (T3), at the end of the Experimental Manipulation phase
Average stressor reactivity (SR) score in the 'whole follow-up' study phase
SR is the residual deviation of an individual from the sample's normative relation between stressor exposure (E) and mental health problems (P). A positive residual indicates more mental health problems than expected based on the normative E-P relationship. A negative residual (negative SR score) indicates less mental health problems than expected. Hence, SR is an inverse continuous expression of an individual's resilience.
Time frame: From week 13 (T4) after enrollment until week 36 after enrollment (T9).
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data will be made findable with a study description and metadata following fairsharing.org conventions. Data will be made interoperable by using common standardized formats (in particular, BIDS for MRI) and a detailed codebook. Open accessibility and data re-use are complicated by the sensitive personal nature of most data and the principled non-anonymizability esp. of MRI data. Participant consent forms will permit sharing of pseudonymized data and biosamples among the sites and with collaborators under the supervision of a Data Use and Access Committee (DUAC). All anonymized data will be made openly accessible through public depositories (in particular, OSF).
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: All anonymized data will be made openly accessible through public depositories (in particular, OSF) upon publication or at latest two years after the termination of the project and will remain accessible for at least ten years upon completion of the study.
Access criteria: Collaborators can get access to the pseudonymized data under the supervision of a Data Use and Access Committee (DUAC). All anonymized data will be made openly accessible through public depositories (in particular, OSF).
Start is estimated for Jun 2025; primary completion for Feb 2027, 20 months later.
Of 1,274 non-industry interventional studies with no phase under Psychological Well-Being, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's planned 20 months is above that.
Counting every sponsor, half of 1,317 studies reached it within 16 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Leibniz-Institut für Resilienzforschung (LIR) gGmbH